Avanos Medical (AVNS) The Citizens Life Sciences Conference 2026 summary

Strategic initiatives and business transformation

• Executed a cost reduction initiative in December, streamlining operations and divesting underperforming assets, including hyaluronic acid and Game Ready rental businesses.

• Acquired Nexus Medical, strengthening the specialty nutrition segment and aligning with a focus on synergistic acquisitions, primarily in specialty nutrition.

• Specialty Nutrition and Pain Management & Recovery are the two core segments, with a goal of mid-single-digit growth, and a higher target for specialty nutrition.

• Mitigated tariff exposure by relocating syringe production from China to Mexico and Cambodia, with most production now benefiting from USMCA and other tariff exemptions.

• Ongoing cost efficiency efforts and a disciplined approach to capital allocation, emphasizing organic growth and targeted M&A.

Financial performance and outlook

• Exceeded full-year revenue and EPS guidance for 2025, providing momentum into 2026 with mid-single-digit growth targets.

• Facing $30 million in syringe-related tariffs in 2026, but confident in earnings expansion through pricing and cost savings.

• Long-term financial target of $1 billion revenue by 2030, to be achieved through organic growth and annual acquisitions slightly larger than the Nexus deal.

• Specialty Nutrition expected to drive higher growth, with Pain Management contributing low- to mid-single-digit growth.

• Guidance for 2026 EPS incorporates $12 million in incremental tariffs, offset by price increases and $15–$20 million in annualized cost savings.

Segment and product highlights

• Specialty Nutrition comprises neonatal (NeoMed, Nexus), long-term (MIC-KEY), and short-term feeding businesses, all projected for mid- to high-single-digit growth.

• CORTRAK and CORGRIP technologies lead the guided tube placement market, with significant runway due to low market penetration.

• Next-generation MIC-KEY feeding tube to launch by year-end, focusing on a smaller, more patient-friendly profile.

• Neonatal Solutions, bolstered by Nexus, serves as a platform for further M&A and product expansion in the NICU channel.

• Short-term feeding segment identified as the area with the most upside due to under-penetration and clear value proposition.